A cross-sectional study published in Cellular and Molecular Neurobiology identifies distinct peripheral neuroinflammatory microRNA signatures associated with pharmacoresistance in temporal lobe epilepsy. The research, led by Rekha Dwivedi and colleagues, examined 80 patients with temporal lobe epilepsy who were stratified into two groups of 40 individuals each: responders and non-responders to treatment. The study aimed to characterize how microRNAs, which act as key post-transcriptional regulators of immune signaling and neuronal excitability, might contribute to the phenomenon of treatment resistance in this specific form of epilepsy.
Temporal lobe epilepsy is a condition where neuroinflammation is increasingly recognized as a critical contributor to both the development of epilepsy and the failure of standard antiepileptic drugs. While microRNAs are known to regulate inflammatory responses and neuronal homeostasis, their specific role in distinguishing patients who respond to medication from those who do not remained incompletely understood prior to this investigation.
The study design involved quantifying the expression levels of ten candidate microRNAs implicated in neuroinflammation, neuronal homeostasis, and apoptosis. These molecules were measured in peripheral blood mononuclear cells using reverse transcription quantitative polymerase chain reaction. The patients were classified according to International League Against Epilepsy criteria for treatment response, ensuring a standardized definition of responders and non-responders. This methodological approach allowed for a direct comparison of the molecular profiles between the two groups, highlighting specific dysregulations associated with pharmacoresistance.
The results revealed a clear divergence in microRNA expression between the two groups. Responders exhibited significantly higher expression of five specific microRNAs: miR-146a, miR-132, miR-139, miR-128, and miR-29b. In contrast, non-responders demonstrated increased expression of a different set of four microRNAs: miR-21, miR-155, miR-223, and miR-34a. This distinct pattern suggests that the neuroinflammatory state of the patient, as reflected in peripheral blood, is fundamentally different in those who achieve seizure control through medication versus those who remain resistant to treatment.
To evaluate the potential clinical utility of these findings, the researchers performed receiver operating characteristic analyses to assess the discriminatory performance of individual microRNAs. Among the ten candidates, miR-128 and miR-146a showed the strongest ability to distinguish between responders and non-responders. MiR-128 achieved an area under the curve of 0.77, while miR-146a reached an area under the curve of 0.75. These values indicate a moderate to good discriminatory power, suggesting that these specific molecules could serve as promising candidate biomarkers for predicting treatment outcomes in temporal lobe epilepsy patients.
Beyond individual expression levels, the study also investigated correlation-based network analyses to understand the co-expression patterns of these microRNAs. The findings indicated that pharmacoresistant temporal lobe epilepsy is associated with altered correlation network organization. This suggests that the dysregulation is not isolated to single molecules but involves a broader shift in the neuroinflammatory regulatory network.
The authors emphasize that these findings support the concept that peripheral neuroimmune alterations are associated with pharmacoresistance. However, the cross-sectional nature of the study means that causality cannot be established. The observed associations indicate that these microRNA patterns are linked to treatment resistance, but further research is needed to determine if they are a cause, a consequence, or a parallel marker of the underlying pathology.
The study highlights the need for further validation in larger, independent cohorts with prospective study designs. While the current sample size of 80 patients provides a strong initial signal, the generalizability of these findings to broader populations requires confirmation.
This research contributes to the growing body of evidence linking neuroinflammation to epilepsy treatment outcomes.
Subject of Research: Peripheral microRNA signatures and correlation networks associated with pharmacoresistance in temporal lobe epilepsy
Article Title: Peripheral Neuroinflammatory MicroRNA Signatures and Altered Correlation Networks Associated with Pharmacoresistance in Temporal Lobe Epilepsy
Article References: Dwivedi, R., Gupta, R., Parihar, J., Pahuja, M., Upadhyay, A. D., Tripathi, M., Dada, R., & Tiwari, P. (2026). Peripheral Neuroinflammatory MicroRNA Signatures and Altered Correlation Networks Associated with Pharmacoresistance in Temporal Lobe Epilepsy. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-026-01791-x
Image Credits: AI Generated
DOI: 10.1007/s10571-026-01791-x
Keywords: temporal lobe epilepsy, pharmacoresistance, microRNA, neuroinflammation, biomarkers, peripheral blood, treatment response, molecular neurobiology, Peripheral, Neuroinflammatory, Signatures, Altered
News Source: Kendall Mcintyre. (November 10, 2026). Blood MicroRNA Patterns Linked to Drug-Resistant Epilepsy. Scienmag.



